8-K filed Aug 4, 2026 at 06:01 ET
IDEAYA Biosciences reported Q2 2026 results with a net loss of $112.5M ($-1.22/share), a wider loss than the prior quarter's $98.5M ($-1.11/share), driven by rising R&D spend ($108.7M vs $95.7M). The company highlighted ongoing NDA submission for darovasertib under RTOR, a new Roche collaboration for IDE892, and a strong cash position of ~$1.24B following a $323.4M June offering. The widening loss and lack of revenue growth (collaboration revenue of $8.9M is immaterial for a pre-commercial biotech) make this a neutral-to-slightly-bearish update, though the pipeline catalysts and cash runway into 2030 provide a floor.